Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides

[1]  H. Vaudry,et al.  Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model , 2016, Neuropharmacology.

[2]  Ketan S. Patil,et al.  Parkinson's disease and age: The obvious but largely unexplored link , 2015, Experimental Gerontology.

[3]  D. Sosnowska,et al.  Age‐Related Decline of Autocrine Pituitary Adenylate Cyclase‐Activating Polypeptide Impairs Angiogenic Capacity of Rat Cerebromicrovascular Endothelial Cells , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  N. Dahiya,et al.  Management of Parkinson׳s disease: Current and future pharmacotherapy. , 2015, European journal of pharmacology.

[5]  P. Chan,et al.  Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys , 2015, Neuroscience.

[6]  J. Waschek,et al.  VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses , 2015, Brain, Behavior, and Immunity.

[7]  D. Vaudry,et al.  Delayed Pituitary Adenylate Cyclase–Activating Polypeptide Delivery After Brain Stroke Improves Functional Recovery by Inducing M2 Microglia/Macrophage Polarization , 2015, Stroke.

[8]  Mao Zhang,et al.  Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[9]  S. Grover,et al.  Psychiatric aspects of Parkinson's disease , 2015, Journal of neurosciences in rural practice.

[10]  B. Mannervik,et al.  Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity , 2014, Neurotoxicity Research.

[11]  M. Li,et al.  Pinocembrin Attenuates 6-OHDA-induced Neuronal Cell Death Through Nrf2/ARE Pathway in SH-SY5Y Cells , 2014, Cellular and Molecular Neurobiology.

[12]  P. Tuchinda,et al.  Autophagy Inhibition by Caffeine Increases Toxicity of Methamphetamine in SH-SY5Y Neuroblastoma Cell Line , 2015, Neurotoxicity Research.

[13]  M. Kajta,et al.  Salsolinol, an Endogenous Compound Triggers a Two-Phase Opposing Action in the Central Nervous System , 2014, Neurotoxicity Research.

[14]  J. Resch,et al.  Augmented cystine–glutamate exchange by pituitary adenylate cyclase‐activating polypeptide signaling via the VPAC1 receptor , 2014, Synapse.

[15]  F. Walter,et al.  Role of the blood-brain barrier in the nutrition of the central nervous system. , 2014, Archives of medical research.

[16]  U. Wenzel,et al.  Amyloid-beta (Aβ₁₋₄₂)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. , 2014, Molecular nutrition & food research.

[17]  A. Buki,et al.  Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury , 2014, Peptides.

[18]  H. Vaudry,et al.  Induction of serpinb1a by PACAP or NGF is required for PC12 cells survival after serum withdrawal , 2014, Journal of neurochemistry.

[19]  S. Vallabhajosula,et al.  PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2. , 2014, Biochimica et biophysica acta.

[20]  R. Bisht,et al.  Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats. , 2014, Neurotoxicology.

[21]  E. Reiman,et al.  Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity , 2014, Neurobiology of Aging.

[22]  Ying Wang,et al.  Trehalose Alleviates PC12 Neuronal Death Mediated by Lipopolysaccharide-Stimulated BV-2 Cells via Inhibiting Nuclear Transcription Factor NF-κB and AP-1 Activation , 2014, Neurotoxicity Research.

[23]  A. Tamas,et al.  Structural and Morphometric Comparison of the Molar Teeth in Pre-eruptive Developmental Stage of PACAP-Deficient and Wild-Type Mice , 2014, Journal of Molecular Neuroscience.

[24]  Yanran Liang,et al.  Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway , 2014, Molecular medicine reports.

[25]  E. Kılıç,et al.  RIFAMPICIN: An antibiotic with brain protective function , 2014, Brain Research Bulletin.

[26]  PACAP Stimulates Functional Recovery after Spinal Cord Injury through Axonal Regeneration , 2014, Journal of Molecular Neuroscience.

[27]  T. Amstislavskaya,et al.  Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model , 2014, Behavioural Brain Research.

[28]  Vincenzo Bonifati,et al.  Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. , 2014, Biochimica et biophysica acta.

[29]  Eun Hye Lee,et al.  Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases , 2014, BMB reports.

[30]  A. Tamas,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Induces Relaxations of Peripheral and Cerebral Arteries, which are Differentially Impaired by Aging , 2014, Journal of Molecular Neuroscience.

[31]  S. Shioda,et al.  PACAP38 Suppresses Cortical Damage in Mice with Traumatic Brain Injury by Enhancing Antioxidant Activity , 2014, Journal of Molecular Neuroscience.

[32]  D. Choi,et al.  A novel synthetic HTB derivative, BECT inhibits lipopolysaccharide-mediated inflammatory response by suppressing the p38 MAPK/JNK and NF-κB activation pathways , 2014, Pharmacological reports : PR.

[33]  B. Vissel,et al.  Advances in non-dopaminergic treatments for Parkinson's disease , 2014, Front. Neurosci..

[34]  I. Kemenes,et al.  Reversal of Age-Related Learning Deficiency by the Vertebrate PACAP and IGF-1 in a Novel Invertebrate Model of Aging: The Pond Snail (Lymnaea stagnalis) , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  Myung‐Sook Choi,et al.  Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo. , 2014, Journal of medicinal food.

[36]  Winnie S. Liang,et al.  Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease , 2014, Neurology.

[37]  A. Tamas,et al.  Investigation of PACAP Fragments and Related Peptides in Chronic Retinal Hypoperfusion , 2014, Journal of ophthalmology.

[38]  Esperanza García,et al.  Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease. , 2014, Toxicology.

[39]  Y. Shin,et al.  Lamotrigine Attenuates Proteasome Inhibition-Induced Apoptosis by Suppressing the Activation of the Mitochondrial Pathway and the Caspase-8- and Bid-Dependent Pathways , 2014, Neurochemical Research.

[40]  A. Tamas,et al.  PACAP Protects Against Inflammatory-Mediated Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease , 2014, Neurotoxicity Research.

[41]  C. Baggio,et al.  Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease , 2014, Neurotoxicity Research.

[42]  Falaq Naz,et al.  Effect of Curcumin on Lifespan, Activity Pattern, Oxidative Stress, and Apoptosis in the Brains of Transgenic Drosophila Model of Parkinson's Disease , 2014, BioMed research international.

[43]  Ágoston Mihalik,et al.  PACAP Application Improves Functional Outcome of Chronic Retinal Ischemic Injury in Rats-Evidence From Electroretinographic Measurements , 2014, Journal of Molecular Neuroscience.

[44]  Xueli Li,et al.  Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinson's disease , 2014, Brain Research Bulletin.

[45]  G. Nicolardi,et al.  Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses , 2014, Innate immunity.

[46]  P. Tuchinda,et al.  Curcumin I Mediates Neuroprotective Effect Through Attenuation of Quinoprotein Formation, p‐p38 MAPK Expression, and Caspase‐3 Activation in 6‐Hydroxydopamine Treated SH‐SY5Y Cells , 2014, Phytotherapy research : PTR.

[47]  D. Ren,et al.  Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway , 2014, Neuropharmacology.

[48]  M. Martinoli,et al.  Resveratrol as a protective molecule for neuroinflammation: a review of mechanisms. , 2014, Current pharmaceutical biotechnology.

[49]  Falaq Naz,et al.  Effect of Epicatechin Gallate Dietary Supplementation on Transgenic Drosophila Model of Parkinson's Disease , 2014, Journal of dietary supplements.

[50]  D. Papy-Garcia,et al.  Structural Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Protofibrils Preventing α-Synuclein Oligomeric Species Toxicity* , 2014, The Journal of Biological Chemistry.

[51]  A. Tamas,et al.  Comparative Protein Composition of the Brains of PACAP-Deficient Mice Using Mass Spectrometry-Based Proteomic Analysis , 2014, Journal of Molecular Neuroscience.

[52]  Yanran Liang,et al.  Rifampicin Protects PC12 Cells from Rotenone-Induced Cytotoxicity by Activating GRP78 via PERK-eIF2α-ATF4 Pathway , 2014, PloS one.

[53]  G. Ning,et al.  Pituitary Adenylate Cyclase Activating Polypeptide Modulates Catecholamine Storage and Exocytosis in PC12 Cells , 2014, PloS one.

[54]  D. Turnbull,et al.  Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.

[55]  T. Miyakawa,et al.  Increased Behavioral and Neuronal Responses to a Hallucinogenic Drug in PACAP Heterozygous Mutant Mice , 2014, PloS one.

[56]  Seung Kim,et al.  Rutin from Dendropanax morbifera Leveille Protects Human Dopaminergic Cells Against Rotenone Induced Cell Injury Through Inhibiting JNK and p38 MAPK Signaling , 2014, Neurochemical Research.

[57]  Debapriya Garabadu,et al.  Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats , 2014, Pharmacology Biochemistry and Behavior.

[58]  Guoqi Zhu,et al.  Neuroprotective Effects of Puerarin on 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine induced Parkinson's Disease Model in Mice , 2014, Phytotherapy research : PTR.

[59]  Jonas Christoffersson,et al.  Autophagy and apoptosis dysfunction in neurodegenerative disorders , 2014, Progress in Neurobiology.

[60]  L. Bubacco,et al.  Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. , 2014, ACS chemical neuroscience.

[61]  K. Brown,et al.  Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells , 2014, Autophagy.

[62]  Yujeong Lee,et al.  Baicalein attenuates astroglial activation in the 1‐methyl‐4‐phenyl‐1,2,3,4‐tetrahydropyridine‐induced Parkinson's disease model by downregulating the activations of nuclear factor‐κB, ERK, and JNK , 2014, Journal of neuroscience research.

[63]  Shang-Der Chen,et al.  Resveratrol Partially Prevents Rotenone-Induced Neurotoxicity in Dopaminergic SH-SY5Y Cells through Induction of Heme Oxygenase-1 Dependent Autophagy , 2014, International journal of molecular sciences.

[64]  Zaiqi Zhang,et al.  Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. , 2014, Fitoterapia.

[65]  Y. Cui,et al.  Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury , 2014, Neurological Sciences.

[66]  H. Sharifi,et al.  Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study , 2014, DARU Journal of Pharmaceutical Sciences.

[67]  L. Bubacco,et al.  LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? , 2014, Journal of Neuroinflammation.

[68]  Z. Helyes,et al.  Neuropeptides in learning and memory , 2013, Neuropeptides.

[69]  B. Gaszner,et al.  Role of neuropeptides in anxiety, stress, and depression: From animals to humans , 2013, Neuropeptides.

[70]  G. Du,et al.  Baicalein Prevents 6-Hydroxydopamine-Induced Mitochondrial Dysfunction in SH-SY5Y Cells via Inhibition of Mitochondrial Oxidation and Up-Regulation of DJ-1 Protein Expression , 2013, Molecules.

[71]  T. Manivasagam,et al.  Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease mice. , 2013, Chemico-biological interactions.

[72]  M. Jimenez-Del-Rio,et al.  Dmp53, basket and drICE gene knockdown and polyphenol gallic acid increase life span and locomotor activity in a Drosophila Parkinson’s disease model , 2013, Genetics and molecular biology.

[73]  A. Giese,et al.  Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. , 2013, Biochimica et biophysica acta.

[74]  A. M. Nayebi,et al.  Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats , 2013, Neuroscience Letters.

[75]  N. Jantaratnotai,et al.  Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia. , 2013, International immunopharmacology.

[76]  N. Braidy,et al.  Neuroprotective Effects of Hesperidin, a Plant Flavanone, on Rotenone-Induced Oxidative Stress and Apoptosis in a Cellular Model for Parkinson's Disease , 2013, Oxidative medicine and cellular longevity.

[77]  M. Mishra,et al.  Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. , 2013, Biochimica et biophysica acta.

[78]  Xiaoqun Duan,et al.  Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway , 2013, Brain Research.

[79]  Neuroprotective Effect of Aqueous Extract of Selaginella delicatula as Evidenced by Abrogation of Rotenone-Induced Motor Deficits, Oxidative Dysfunctions, and Neurotoxicity in Mice , 2013, Cellular and Molecular Neurobiology.

[80]  W. Stühmer,et al.  Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model , 2013, Glia.

[81]  M. Beal,et al.  Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases , 2013, Molecular and Cellular Neuroscience.

[82]  D. Choi,et al.  Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson's Disease , 2013, Mediators of inflammation.

[83]  Qiaoling He,et al.  Puerarin attenuates neuronal degeneration and blocks oxidative stress to elicit a neuroprotective effect on substantia nigra injury in 6-OHDA-lesioned rats , 2013, Brain Research.

[84]  M. Chesselet,et al.  PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice , 2013, Neuroscience.

[85]  N. Toni,et al.  Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus , 2013, Front. Neurosci..

[86]  Z. Gazova,et al.  Amyloid aggregation of lysozyme: The synergy study of red wine polyphenols , 2013, Proteins.

[87]  T. Graeber,et al.  Doxycycline Alters Metabolism and Proliferation of Human Cell Lines , 2013, PloS one.

[88]  A. Rodriguez-Mateos,et al.  Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. , 2013, Antioxidants & redox signaling.

[89]  G. Forloni,et al.  A new face for old antibiotics: tetracyclines in treatment of amyloidoses. , 2013, Journal of medicinal chemistry.

[90]  Small molecules interacting with α-synuclein: antiaggregating and cytoprotective properties , 2013, Amino Acids.

[91]  PACAP Protects Against Salsolinol-Induced Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease , 2013, Journal of Molecular Neuroscience.

[92]  S. Karuppagounder,et al.  Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats , 2013, Neuroscience.

[93]  D. Choi,et al.  Resveratrol Confers Protection against Rotenone-Induced Neurotoxicity by Modulating Myeloperoxidase Levels in Glial Cells , 2013, PloS one.

[94]  Min Zhu,et al.  Oxidized quercetin inhibits α-synuclein fibrillization. , 2013, Biochimica et biophysica acta.

[95]  Jue-an Jiang,et al.  Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. , 2013, International journal of molecular medicine.

[96]  R. Lazzaroni,et al.  Free radical scavenging by natural polyphenols: atom versus electron transfer. , 2013, The journal of physical chemistry. A.

[97]  K. Andreasson,et al.  Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease , 2013, Experimental Neurology.

[98]  R. Thangavel,et al.  Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol , 2013, Neurochemistry International.

[99]  O. Hwang.  Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.

[100]  Nagaraja Haleagrahara,et al.  Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. , 2013, The Journal of toxicological sciences.

[101]  A. Tamas,et al.  Examination of Calcium-Binding Protein Expression in the Inner Ear of Wild-Type, Heterozygous and Homozygous Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)-Knockout Mice in Kanamycin-Induced Ototoxicity , 2013, Neurotoxicity Research.

[102]  G. Le Douaron,et al.  MALDI Mass Spectrometry Imaging of 1-Methyl-4-phenylpyridinium (MPP+) in Mouse Brain , 2013, Neurotoxicity Research.

[103]  L. Hurley,et al.  Protective Effects of Curcumin Against Rotenone and Salsolinol-Induced Toxicity: Implications for Parkinson’s Disease , 2013, Neurotoxicity Research.

[104]  T. Manivasagam,et al.  Therapeutic Attenuation of Neuroinflammation and Apoptosis by Black Tea Theaflavin in Chronic MPTP/Probenecid Model of Parkinson’s Disease , 2013, Neurotoxicity Research.

[105]  Yanran Liang,et al.  Rifampicin and Parkinson’s disease , 2013, Neurological Sciences.

[106]  Jun Liu,et al.  Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.

[107]  Shui-Tein Chen,et al.  Chemical and biological evaluation of nephrocizin in protecting nerve growth factor-differentiated PC12 cells by 6-hydroxydopamine-induced neurotoxicity. , 2012, Phytochemistry.

[108]  M. Nagy,et al.  In Vitro Antioxidant Activities of Three Red Wine Polyphenols and Their Mixtures: An Interaction Study , 2012, Molecules.

[109]  H. Schiöth,et al.  Intranasal Treatment of Central Nervous System Dysfunction in Humans , 2012, Pharmaceutical Research.

[110]  A. Giese,et al.  Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro. , 2012, Biochimica et biophysica acta.

[111]  P. Grammas,et al.  Age-related decrease in cerebrovascular-derived neuroprotective proteins: effect of acetaminophen. , 2012, Microvascular research.

[112]  K. Lim,et al.  AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease , 2012, The Journal of Neuroscience.

[113]  Wusi Qiu,et al.  The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury , 2012, The journal of trauma and acute care surgery.

[114]  S. S. Agrawal,et al.  Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson's Disease in Albino Wistar Rats , 2012, Cardiovascular psychiatry and neurology.

[115]  R. Shi,et al.  Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. , 2012, The Journal of nutrition.

[116]  Y. Ho,et al.  Potential of D‐cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials , 2012, The Kaohsiung journal of medical sciences.

[117]  Yu-Qing Wu,et al.  Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-κB pathway. , 2012, Journal of neurotrauma.

[118]  T. Dóczi,et al.  Effect of PACAP in Central and Peripheral Nerve Injuries , 2012, International journal of molecular sciences.

[119]  M. Martinoli,et al.  Quercetin and Sesamin Protect Dopaminergic Cells from MPP+-Induced Neuroinflammation in a Microglial (N9)-Neuronal (PC12) Coculture System , 2012, Oxidative medicine and cellular longevity.

[120]  Xiaochun Chen,et al.  Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway , 2012, BMC Complementary and Alternative Medicine.

[121]  L. Eiden.  PACAP and Cellular Protection , 2012 .

[122]  T. Atsumi,et al.  Neuroprotective Effect of Endogenous Pituitary Adenylate Cyclase-Activating Polypeptide on Spinal Cord Injury , 2012, Journal of Molecular Neuroscience.

[123]  M. Figueiredo-Pereira,et al.  Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP , 2012, Cell Death and Disease.

[124]  Christopher M. Dobson,et al.  Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.

[125]  K. Shindler,et al.  Resveratrol Neuroprotection in a Chronic Mouse Model of Multiple Sclerosis , 2012, Front. Neur..

[126]  A. Lakatos,et al.  PACAP is an Endogenous Protective Factor—Insights from PACAP-Deficient Mice , 2012, Journal of Molecular Neuroscience.

[127]  Sara M. Levens,et al.  Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment , 2012, The Journal of Neuroscience.

[128]  C. Kusumoto,et al.  Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells , 2012, Journal of clinical biochemistry and nutrition.

[129]  A. Ebrahimi,et al.  Natural polyphenols against neurodegenerative disorders: Potentials and pitfalls , 2012, Ageing Research Reviews.

[130]  T. Kuo,et al.  Minocycline prevents paraquat-induced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. , 2012, Toxicology letters.

[131]  P. Shaw,et al.  Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? , 2012, Journal of ethnopharmacology.

[132]  D. Reglodi,et al.  The behavioral phenotype of pituitary adenylate-cyclase activating polypeptide-deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger–Westphal nucleus, ventral lateral septum, and dorsal raphe n , 2012, Neuroscience.

[133]  K. Yung,et al.  Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. , 2012, ACS chemical neuroscience.

[134]  J. Loike,et al.  Neurodegeneration and inflammation in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[135]  M. Touvier,et al.  Total and specific polyphenol intakes in midlife are associated with cognitive function measured 13 years later. , 2012, The Journal of nutrition.

[136]  B. Sambrano,et al.  Antibiotics used in nonbacterial dermatologic conditions , 2012, Dermatologic therapy.

[137]  S. Mandel,et al.  Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols. , 2012, Frontiers in bioscience.

[138]  Ting Zhang,et al.  Therapeutic Effects of Rapamycin on MPTP-Induced Parkinsonism in Mice , 2012, Neurochemical Research.

[139]  Yong-Mei Zhang,et al.  Effects of pituitary adenylate cyclase activating polypeptide on CD4(+)/CD8(+) T cell levels after traumatic brain injury in a rat model. , 2012, World journal of emergency medicine.

[140]  Sucheol Gil,et al.  Doxycycline impairs neutrophil migration to the airspaces of the lung in mice exposed to intratracheal lipopolysaccharide , 2012, Journal of Inflammation.

[141]  Abraham Weizman,et al.  Peptide-binding GRP78 protects neurons from hypoxia-induced apoptosis , 2011, Apoptosis.

[142]  S. Koyama,et al.  Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease , 2011, The Journal of Neuroscience.

[143]  P. Fisher,et al.  Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics , 2011, Journal of cellular physiology.

[144]  J. Waschek,et al.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis , 2011, ASN neuro.

[145]  Yanran Liang,et al.  Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation , 2011, Brain Research.

[146]  H. Vaudry,et al.  PACAP and a novel stable analog protect rat brain from ischemia: Insight into the mechanisms of action , 2011, Peptides.

[147]  Y. Ho,et al.  Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia , 2011, Behavioural Brain Research.

[148]  A. Scalbert,et al.  The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. , 2011, The Journal of nutrition.

[149]  P. Ng,et al.  Use of prokinetics in the preterm infant , 2011, Current opinion in pediatrics.

[150]  J. Cooper,et al.  Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line , 2011, Neuroscience Research.

[151]  A. Tamas,et al.  Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. , 2011, Current pharmaceutical design.

[152]  T. Joh,et al.  Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death* , 2011, The Journal of Biological Chemistry.

[153]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[154]  R. Klein,et al.  Repairing the parkinsonian brain with neurotrophic factors , 2011, Trends in Neurosciences.

[155]  C. Oliveira,et al.  Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD , 2011, Parkinson's disease.

[156]  T. Walle.  Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[157]  Eun-mee Kim,et al.  Role of matrix metalloproteinase‐3 in neurodegeneration , 2011, Journal of neurochemistry.

[158]  A. Tamas,et al.  Mice Deficient in Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) are More Susceptible to Retinal Ischemic Injury In Vivo , 2011, Neurotoxicity Research.

[159]  S. Hung,et al.  Effects of Combinatorial Treatment with Pituitary Adenylate Cyclase Activating Peptide and Human Mesenchymal Stem Cells on Spinal Cord Tissue Repair , 2010, PloS one.

[160]  M. Leist,et al.  Neuroprotection by Minocycline Caused by Direct and Specific Scavenging of Peroxynitrite* , 2010, The Journal of Biological Chemistry.

[161]  Jong-Wook Park,et al.  Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia. , 2010, The Journal of nutritional biochemistry.

[162]  Zhongxiang Fang,et al.  Encapsulation of polyphenols – a review , 2010 .

[163]  Fanling Meng,et al.  The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. , 2010, Biochemistry.

[164]  J. Troncoso,et al.  Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function , 2010, Proceedings of the National Academy of Sciences.

[165]  Hee-Sun Kim,et al.  α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1 , 2010, The Journal of Immunology.

[166]  S. Shioda,et al.  Regulation of Oxidative Stress by Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Mediated by PACAP Receptor , 2010, Journal of Molecular Neuroscience.

[167]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[168]  Xiaomin Wang,et al.  Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease , 2010 .

[169]  An-Li Wang,et al.  Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats , 2010, Behavioural Brain Research.

[170]  S. Mandel,et al.  Low Dosage of Rasagiline and Epigallocatechin Gallate Synergistically Restored the Nigrostriatal Axis in MPTP-Induced Parkinsonism , 2010, Neurodegenerative Diseases.

[171]  Lloyd A Greene,et al.  Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.

[172]  M. Tohyama,et al.  Increased Stathmin1 Expression in the Dentate Gyrus of Mice Causes Abnormal Axonal Arborizations , 2010, Neuroscience Research.

[173]  Sun,et al.  Rifampicin inhibits apoptosis in rotenone-induced differentiated PC12 cells by ameliorating mitochondrial oxidative stress , 2010 .

[174]  S. Shioda,et al.  Neuroprotective Effect of PACAP Against NMDA-Induced Retinal Damage in the Mouse , 2010, Journal of Molecular Neuroscience.

[175]  B. Fauconneau,et al.  Neuroprotective Effect of PACAP on Translational Control Alteration and Cognitive Decline in MPTP Parkinsonian Mice , 2010, Neurotoxicity Research.

[176]  T. Pan,et al.  Rapamycin protects against rotenone-induced apoptosis through autophagy induction , 2009, Neuroscience.

[177]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery , 2009, Pharmacological Reviews.

[178]  A. Whitworth,et al.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.

[179]  D. Dexter,et al.  Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease , 2009, Journal of neurochemistry.

[180]  T. Joh,et al.  Doxycycline is Neuroprotective Against Nigral Dopaminergic Degeneration by a Dual Mechanism Involving MMP-3 , 2009, Neurotoxicity Research.

[181]  A. H. Tsang,et al.  Oxidative and nitrosative stress in Parkinson's disease. , 2009, Biochimica et biophysica acta.

[182]  Volker Ullrich,et al.  Peroxynitrite as regulator of vascular prostanoid synthesis. , 2009, Archives of biochemistry and biophysics.

[183]  W. Noble,et al.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding , 2009, Prion.

[184]  W. Banks,et al.  Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[185]  G. Forloni,et al.  Tetracyclines and prion infectivity. , 2009, Infectious disorders drug targets.

[186]  Y. Suh,et al.  Minocycline and neurodegenerative diseases , 2009, Behavioural Brain Research.

[187]  M. Tello,et al.  Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin. , 2009, Current pharmaceutical biotechnology.

[188]  L. Greene,et al.  RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation , 2008, The Journal of Neuroscience.

[189]  G. Miller,et al.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity , 2008, Neuropeptides.

[190]  A. Pinhasov,et al.  Involvement of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and its Receptors in the Mechanism of Antidepressant Action , 2008, Journal of Molecular Neuroscience.

[191]  Ru-jing Ren,et al.  Neuroprotective effects of PACAP27 in mice model of Parkinson’s disease involved in the modulation of KATP subunits and D2 receptors in the striatum , 2008, Neuropeptides.

[192]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[193]  Shey‐Lin Wu,et al.  Effects of d-cycloserine on the behavior and ERK activity in the amygdala: Role of individual anxiety levels , 2008, Behavioural Brain Research.

[194]  M. Martinoli,et al.  Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation , 2008, Journal of neuroscience research.

[195]  A. Minagar,et al.  Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. , 2008, Archives of neurology.

[196]  I. Onyango.  Mitochondrial Dysfunction and Oxidative Stress in Parkinson’s Disease , 2008, Neurochemical Research.

[197]  M. Robinson,et al.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention , 2007, Neurochemistry International.

[198]  Grace Yim,et al.  Antibiotics as signalling molecules , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.

[199]  J. Houeto,et al.  Neuroprotective effects of pituitary adenylate cyclase–activating polypeptide (PACAP) in MPP+‐induced alteration of translational control in Neuro‐2a neuroblastoma cells , 2007, Journal of neuroscience research.

[200]  Yih-Ru Wu,et al.  Tumor necrosis factor‐α promoter polymorphism is associated with the risk of Parkinson's disease , 2007 .

[201]  J. Billard,et al.  Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by d‐cycloserine , 2007, The European journal of neuroscience.

[202]  Jie Xu,et al.  Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an α-Synuclein multimer , 2007, Brain Research.

[203]  J. Roh,et al.  Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation , 2007, Stroke.

[204]  M. Youdim,et al.  Iron and α-synuclein in the substantia nigra of MPTP-treated mice , 2007, Journal of Molecular Neuroscience.

[205]  S. Lorenzl,et al.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2007, NeuroMolecular Medicine.

[206]  R. Burke,et al.  Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease , 2006, Proceedings of the National Academy of Sciences.

[207]  Sufen Yang,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 38 and PACAP4–6 Are Neuroprotective through Inhibition of NADPH Oxidase: Potent Regulators of Microglia-Mediated Oxidative Stress , 2006, Journal of Pharmacology and Experimental Therapeutics.

[208]  Erwan Bezard,et al.  Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.

[209]  T. Joh,et al.  Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease , 2006, Experimental & Molecular Medicine.

[210]  A. Tamas,et al.  Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats , 2006, Neuropeptides.

[211]  A. Tamas,et al.  Comparative Study of the Effects of PACAP in Young, Aging, and Castrated Males in a Rat Model of Parkinson's Disease , 2006, Annals of the New York Academy of Sciences.

[212]  A. Tamas,et al.  Protective Effects of PACAP in Excitotoxic Striatal Lesion , 2006, Annals of the New York Academy of Sciences.

[213]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[214]  Jack J. Chen,et al.  Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[215]  S. Shioda,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[216]  Y. Oida,et al.  Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain , 2006, Brain Research.

[217]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[218]  R. Nagatomi,et al.  Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. , 2006, The American journal of clinical nutrition.

[219]  A H V Schapira,et al.  Present and future drug treatment for Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[220]  C. Carpenter,et al.  Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. , 2005, The Journal of nutritional biochemistry.

[221]  N. Wood,et al.  Molecular pathogenesis of Parkinson's disease. , 2005, Human molecular genetics.

[222]  J. Steeves,et al.  Minocycline as a Neuroprotective Agent , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[223]  Gang Wang,et al.  PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone , 2005, FEBS letters.

[224]  S. M. Park,et al.  Proteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.

[225]  Ling Lin,et al.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.

[226]  A. Foster,et al.  Role of the GLT‐1 subtype of glutamate transporter in glutamate homeostasis: the GLT‐1‐preferring inhibitor WAY‐855 produces marginal neurotoxicity in the rat hippocampus , 2005, The European journal of neuroscience.

[227]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[228]  M. Bennett.  The role of α-synuclein in neurodegenerative diseases , 2005 .

[229]  N. Sonenberg,et al.  Regulation of cap-dependent translation by eIF4E inhibitory proteins , 2005, Nature.

[230]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[231]  Gary Williamson,et al.  Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.

[232]  A. Tamas,et al.  Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats , 2004, Regulatory Peptides.

[233]  Masatoshi Morita,et al.  Motor hyperactivity caused by a deficit in dopaminergic neurons and the effects of endocrine disruptors: a study inspired by the physiological roles of PACAP in the brain , 2004, Regulatory Peptides.

[234]  Shijie Jin,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells , 2004, Multiple sclerosis.

[235]  Carlos Matute,et al.  Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.

[236]  Yiping Gu,et al.  Effect of IGF‐1 on the balance between autophagy of dysfunctional mitochondria and apoptosis , 2004, FEBS letters.

[237]  Targeting a-Synuclein in Parkinson's Disease , 2004 .

[238]  V. Uversky,et al.  Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils , 2004 .

[239]  P. LeWitt.  Clinical trials of neuroprotection for Parkinson’s disease , 2004, Neurology.

[240]  D. Reglodi,et al.  Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. , 2004, Current pharmaceutical design.

[241]  I. Duncan,et al.  Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro. , 2004, Neuron glia biology.

[242]  J. Girault,et al.  Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. , 2004, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[243]  A. Tamas,et al.  Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson’s disease , 2004, Behavioural Brain Research.

[244]  M. E. Eichler,et al.  Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[245]  L. Petrucelli,et al.  Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system , 2004, Annals of medicine.

[246]  T. Lanthorn.  D-Cycloserine: Agonist turned antagonist , 1994, Amino Acids.

[247]  Todd B. Sherer,et al.  Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.

[248]  A. Harrison,et al.  Minocycline-induced lupus: a case series. , 2003, The New Zealand medical journal.

[249]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[250]  M. Delgado,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase- Activating Polypeptide Inhibit the Production of Inflammatory Mediators by Activated Microglia , 2022 .

[251]  M. Abe,et al.  Drug-induced hepatitis with autoimmune features during minocycline therapy. , 2003, Internal medicine.

[252]  M. Delgado.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. , 2002, Biochemical and biophysical research communications.

[253]  M. Delgado,et al.  Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microglia , 2002, Glia.

[254]  M. Delgado.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. , 2002, Biochemical and biophysical research communications.

[255]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[256]  S. Dower,et al.  Toll-Like Receptor (TLR)2 and TLR4 in Human Peripheral Blood Granulocytes: A Critical Role for Monocytes in Leukocyte Lipopolysaccharide Responses1 , 2002, The Journal of Immunology.

[257]  B. Foxwell,et al.  Potential of rifamides to inhibit TNF-induced NF-κB activation , 2002 .

[258]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[259]  A. Tolkovsky,et al.  Mitochondrial disappearance from cells: a clue to the role of autophagy in programmed cell death and disease? , 2002, Biochimie.

[260]  É. Fernandez,et al.  Transcriptional and post-transcriptional regulation of Tyrosine Hydroxylase messenger RNA in PC12 cells during persistent stimulation by VIP and PACAP38: differential regulation by protein kinase A and protein kinase C -dependent pathways , 2002, Neuropeptides.

[261]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[262]  P. Carvey,et al.  Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .

[263]  S. Paul,et al.  Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons , 2001, Neuroscience Letters.

[264]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[265]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[266]  M. Clemens.  Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins , 2001, Journal of cellular and molecular medicine.

[267]  J. Koistinaho,et al.  Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.

[268]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[269]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[270]  R. Yu,et al.  Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE),†,‡ , 2001, Drug metabolism reviews.

[271]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[272]  G. Forloni,et al.  Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.

[273]  R. Jope,et al.  Peroxynitrite modulates the activation of p38 and extracellular regulated kinases in PC12 cells. , 2000, Archives of biochemistry and biophysics.

[274]  P. Shashidharan,et al.  Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson’s disease , 2000, Journal of Neurology.

[275]  J. Schneider,et al.  Effects of the partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys , 2000, Brain Research.

[276]  J. Scholz,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP-27) enhances tyrosine hydroxylase activity in the nucleus accumbens of the rat , 1999, Neuropeptides.

[277]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[278]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[279]  L. Larivière,et al.  Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4) , 1999, The Journal of experimental medicine.

[280]  A. Schapira.  Science, medicine, and the future: Parkinson's disease. , 1999, BMJ.

[281]  N. Takei,et al.  Neurotrophic and neuroprotective effects of pituitary adenylate cyclase‐activating polypeptide (pACAP) on mesencephalic dopaminergic neurons , 1998, Journal of neuroscience research.

[282]  Shigeo Hirai,et al.  NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.

[283]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[284]  E. Hirsch,et al.  Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[285]  Turan M. Itil,et al.  A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .

[286]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[287]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[288]  David R. Kaplan,et al.  Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.

[289]  A. F. Schinder,et al.  Mitochondrial Dysfunction Is a Primary Event in Glutamate Neurotoxicity , 1996, The Journal of Neuroscience.

[290]  R. Shigemoto,et al.  Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study , 1996, The Journal of comparative neurology.

[291]  M. Hediger,et al.  Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate , 1996, Neuron.

[292]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[293]  M. Palkovits,et al.  Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei , 1995, Brain Research.

[294]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[295]  T. Tabira,et al.  Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. , 1994, The American journal of pathology.

[296]  M. Gossen,et al.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[297]  A. Guidotti,et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) potently enhances tyrosine hydroxylase (TH) expression in adrenal chromaffin cells. , 1994, Life sciences.

[298]  V. Perry,et al.  Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain , 1990, Neuroscience.

[299]  M. Bolanowski,et al.  d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed inXenopus oocytes , 1990, Brain Research.

[300]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[301]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[302]  J. Monahan,et al.  d-Cycloserine: A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics , 1989, Neuroscience Letters.

[303]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[304]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[305]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[306]  M. Canady,et al.  Rifampicin: an immunosuppressant? , 1972, Lancet.